Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000 and was listed on the Shenzhen Stock Exchange Growth Enterprise Board (stock code 300255) on August 19, 2011. At present, the registered capital is 935 million yuan, with a total asset of 3.5 billion yuan. It has four production bases, nine subsidiaries, two overseas companies, and two joint ventures. The company is a biochemical pharmaceutical enterprise that integrates research and development, production, sales, and import and export trade. In the field of heparin, it is a key high-tech enterprise with a complete heparin industry chain, ranging from crude heparin to low molecular weight heparin injection products. It is one of the leading enterprises in the domestic heparin series of drugs. Since its establishment, the company has focused on the research, development, production and sales of drugs for cardiovascular and cerebrovascular diseases, diabetes drugs and anti-cancer drugs, and has actively expanded medical equipment, beauty, precision medicine and other fields. Its products are exported to many countries in the world. The company focuses on the development of new drugs and establishes Changshan Pharmaceutical Research Institute, aiming to build a brand new drug research and information sharing center. By collecting and analyzing the latest cutting-edge information of new drugs, selecting key R&D varieties, integrating various R&D resources, and introducing and cultivating R&D talents, the company plays a leading role in innovation and serves the company's strategic goal of vigorously developing innovative drugs in the medium to long term, It is an important measure for the implementation of the company's strategy and has positive significance for the company's future development. The company invests a large amount of funds annually for technological innovation and has achieved significant breakthroughs in innovation and cooperation. In the next 1 to 3 years, low molecular weight heparin water injection formulations will enter the European and American markets, and the company will achieve the "Double Hundred" goal: to enter the top 100 Chinese pharmaceutical enterprises, with sales revenue exceeding 10 billion yuan, and build Changshan Pharmaceutical into an international first-class innovative new drug research and development and production enterprise. In order to achieve these goals, we will continue to strengthen research and development investment on the basis of our existing product line, and increase innovative product projects with independent intellectual property rights. |
| Headquarter | Shijiazhuang |
| Establish Date | 9/28/2000 |
| Listed Code | 300255.SZ |
| Listed Date | 8/19/2011 |
| Chairman | Gao Xiaodong. |
| CEO | Cai Hao. |
| Website | www.hbcsbio.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
